leisure time -WSS

leisure time

author：comprehensive 2025-09-07 11:13:23 - browse：78

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout LOUD podcast: What to know about H5N1 bird flu

WSS

Tesla recalling nearly 16,000 of its 2021

Study: Adult vaccinations pay for themselves in societal benefits

Use wet bulb globe temperature, not heat index, to protect workers

Divers poised to search for children washed away in Pennsylvania flash flood

Winning ticket for $1 billion Powerball jackpot sold in California

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

hotspot

leisure time

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Judge rejects Trump's request to move Stormy Daniels hush

Medical leaders decry Supreme Court decision on affirmative action

Why Congress must ban federal programs from using QALYs

Hepatitis C has a cure — but many Americans still lack access to it

First recipient of genetically engineered pig kidney has died

Hepatitis C has a cure — but many Americans still lack access to it

Affordable Connectivity Program vital to health care, experts say

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stanford president's case begs question: Who takes blame?

entertainment

Brain worms: The science behind RFK Jr.'s parasitic infection

Tocagen's brain cancer gene therapy trial continues. Investors worry

DeSantis talks Trump, trans issues and 'what wokeness is'

Affordable Connectivity Program vital to health care, experts say

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Stanford president faces new allegations over 1999 paper

hotspot

explore

explore

Wikipedia